Buprenorphine is a semi-synthetic opioid analgesic derived from thebaine. It is a partial mu-opioid receptor agonist and a kappa-opioid receptor antagonist. In the 2mg strength, it is primarily used in India for the management of moderate to severe acute pain (often post-operative) and as a component of opioid substitution therapy (OST) for opioid dependence, though the latter typically uses a sublingual formulation. It provides potent analgesia with a ceiling effect on respiratory depression, making it safer than full agonists in overdose.
Adult: **Pain:** Sublingual: 0.2-0.4 mg every 6-8 hrs as needed. IM/IV: 0.3 mg every 6-8 hrs. **OST:** Induction and maintenance doses are highly individualized, starting typically at 2-4 mg sublingually, titrated upwards to 8-24 mg/day based on control of withdrawal symptoms. Must be initiated under supervision.
Note: **Sublingual tablet:** Place under the tongue and allow to dissolve completely (takes 5-10 minutes). Do not chew, swallow, or ingest for at least 5 minutes after dissolution. Avoid eating or drinking until tablet is fully dissolved. **For OST:** Administration is directly observed at the center initially. Take-home doses may be permitted after stabilization as per program rules.
Buprenorphine binds with high affinity and slow dissociation to mu-opioid receptors in the central nervous system. As a partial agonist, it produces a sub-maximal analgesic effect compared to full agonists like morphine. It also acts as an antagonist at the kappa-opioid receptor, which may contribute to its unique effects, including a lower incidence of dysphoria.
Pregnancy: Pregnancy Category C (US FDA). Use only if potential benefit justifies potential fetal risk. May cause neonatal opioid withdrawal syndrome (NOWS) with prolonged use. In opioid-dependent pregnant women, medication-assisted therapy (MAT) with buprenorphine monotherapy is preferred over untreated addiction or methadone in some protocols, but requires specialist management.
Driving: May impair mental and/or physical abilities required for driving or operating machinery. Patients should be cautioned, especially during dose initiation and titration.
| Benzodiazepines (e.g., Alprazolam, Diazepam) | Profound sedation, respiratory depression, coma, and death. Risk is highest with parenteral use and abuse. | Major - Contraindicated for non-medical use. Combined use in therapy requires strict medical supervision. |
| Other CNS Depressants (Alcohol, Barbiturates, Sedative-hypnotics) | Additive CNS depression, increased risk of respiratory depression and hypotension. | Major |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Ritonavir, Grapefruit juice) | Increased buprenorphine plasma levels, potentiating effects and toxicity. | Moderate |
| CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin, St. John's Wort) | Decreased buprenorphine plasma levels, potentially reducing efficacy and precipitating withdrawal. | Moderate |
| Full Opioid Agonists (e.g., Morphine, Methadone, Fentanyl) | Buprenorphine may block the effects of full agonists and precipitate acute withdrawal in opioid-dependent patients. | Major |
| Serotonergic Drugs (SSRIs, SNRIs, TCAs, Tramadol) | Potential increased risk of serotonin syndrome. | Moderate |
| Anticholinergics | Increased risk of urinary retention and constipation. | Moderate |
| Antihypertensives | Potentiation of hypotensive effects. | Moderate |
Same composition (Buprenorphine (2mg)), different brands: